Company: KNRX
Filing Date: 2025-09-02
Form Type: F-1/A
Source: 0001493152-25-012564
Chunk: 77

Company: KNOREX LTD.
Filing Date: 2025-09-02
Form: F-1/A
Chunk 77
---
 to the Company. As of the date of this prospectus, the
Reorganization was completed and the Company now owns 100% of Knorex SG. In consideration thereof, the Company had allotted and issued
an aggregate of 22,477,825 Class A Ordinary Shares and 4,780,555 Class B Ordinary Shares of the Company to the shareholders of Knorex
SG and certain other persons, in accordance with and subject to the terms of the Restructuring Agreement.

Pursuant to the Restructuring
Agreement, the Company issued warrants to shareholders of the Company, who were previously shareholders of Knorex SG, and certain other
persons in exchange for warrants previously issued to them by Knorex SG. The warrants issued by the Company included: (i) a total of
4,692,100 warrants with an aggregate amount of US$7,722,941 and (ii) a set of warrants with an aggregate amount of US$836,597, both exercisable
for the same type of securities the Company issues in its next immediate equity financing round that involves the issuance of preference
shares or preferred securities in the Company to raise funds for the Company (or Class A Ordinary Shares if such immediate equity financing
round is our Company’s initial public offering). The expiration dates of the warrants described in (i) and (ii) ranged from
December 2024 to December 2026. In January 2025, a total of 164,713 warrants described in (i) above were exercised to subscribe for 164,713 Class A Ordinary Shares with the remaining 4,527,387 warrants being cancelled in exchange for the issuance of a total of 4,527,387 warrants with an aggregate amount of US$7,073,397.74 to extend the expiration dates to a period range from March 2026 to December 2027.The expiration dates of the warrants described
in (ii)were extended to March 2027. The exercise
price for the warrants described in (ii) above with an aggregate amount of US$836,597 shall be determined by reference to the issue price
of the types of securities and shall be equal to the issue price of the securities being offered in the next immediate equity funding
round (or equal to 65% of the issue price of Class A Ordinary Shares if the next immediate equity funding round is the Company’s
initial public offering), subject to adjustment for certain dilutive events such as, among other things,